Overview

Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma

Status:
Completed
Trial end date:
2018-08-09
Target enrollment:
Participant gender:
Summary
This randomization discontinuation trial will allow for concomitant evaluation of the following: - Side effects and benefits of immediate continuation of Trabectedin after the sixth cycle - Side effects and benefits of a drug holiday
Phase:
Phase 2
Details
Lead Sponsor:
Centre Oscar Lambret
Collaborators:
French Sarcoma Group
Groupe d’études des Tumeurs Osseuses
Groupe Sarcome Français
Study Group of Bone Tumors
Treatments:
Trabectedin